Titolo	Data di pubblicazione	Autore(i)
1	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.	2016	Erriquez, J; Olivero, M; Mittica, G; Scalzo, Ms; Vaira, M; De Simone, M; Ponzone, R; Katsaros, D; Aglietta, M; Calogero, R; Di Renzo, Mf; Valabrega, G
2	What can we learn from the ZOOM trial? - Authors' reply.	2013	Amadori D;Mercatali L;Nanni O;Aglietta M;Alessi B;Gianni L;Farina G;Gaion F;Bertoldo F;Santini D;Rondena R;Bogani P;Ripamonti CI;Ibrahim T
3	Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study	2008	MONTEMURRO F; REDANA S; NOLE' F; DONADIO M; JACOMUZZI ME; VALABREGA G; VIALE G; SAPINO A; AGLIETTA M
4	Veliparib: a new therapeutic option in ovarian cancer?	2019	Ghisoni, Eleonora; Giannone, Gaia; Tuninetti, Valentina; Genta, Sofia; Scotto, Giulia; Aglietta, Massimo; Sangiolo, Dario; Mittica, Gloria; Valabrega, Giorgio
5	Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.	2011	Joensuu H; De Braud F; Grignani G; De Pas T; Spitalieri G; Coco P; Spreafico C; Boselli S; Toffalorio F; Bono P; Jalava T; Kappeler C; Aglietta M; Laurent D; Casali PG.
6	Vasculogenic potential of long term repopulating cord blood progenitors	2004	DROETTO S; VIALE A; PRIMO L; JORDANEY N; BRUNO S; PAGANO M; PIACIBELLO W; BUSSOLINO F; AGLIETTA M
7	Validated Nomogram Predicting 6-Month Survival in Pancreatic Cancer Patients Receiving First-Line 5-Fluorouracil, Oxaliplatin, and Irinotecan	2019	Fornaro L.; Leone F.; Vienot A.; Casadei-Gardini A.; Vivaldi C.; Lievre A.; Lombardi P.; De Luca E.; Vernerey D.; Sperti E.; Musettini G.; Satolli M.A.; Edeline J.; Spadi R.; Neuzillet C.; Falcone A.; Pasquini G.; Clerico M.; Passardi A.; Buscaglia P.; Meurisse A.; Aglietta M.; Brac C.; Vasile E.; Montagnani F.
8	Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer.	2010	Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M.
9	Tumori Rari	2003	AGLIETTA M; CANTU' G; CASLI PG; DOGLIOTTI L; GRIGNANI G; LABIANCA R; LICITRA L; MAGGI P; TAINO R
10	Tumor cell purging by ex vivo expansion of hemopoietic stem cells from breast cancer patients combined with targeting ErbB receptors	2006	F. LEONE; G. CAVALLONI; M. GUNETTI; Y. PIGNOCHINO; W. PIACIBELLO; M. AGLIETTA
11	TROMBOCITEMIA ESSENZIALE (Sindromi Mieloproliferative Croniche)	2000	AGLIETTA M; CAPALDI A; ROTA-SCALABRINI D
12	Trisomy 8 and an unbalanced t(5;17)(q11;p11) characterize two karyotypically independent clones in a case of idiopathic myelofibrosis evolving to acute nonlymphoid leukemia.	1991	KERIM S ;REGE-CAMBRIN G ;SCARAVAGLIO P ;GODIO L ;SAGLIO G ;AGLIETTA M
13	Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients	2017	Cascinu, Stefano; Rosati, Gerardo; Bilancia, Domenico; Nasti, Guglielmo; Iaffaioli, Rosario Vincenzo; Lonardi, Sara; Zagonel, Vittorina; Zaniboni, Alberto; Marchetti, Paolo; Romiti, Adriana; Leone, Francesco; Aglietta, Massimo; Giordano, Monica; Corsi, Domenico C.; Ferraãº, Francesco; Labianca, Roberto; Mosconi, Stefania; Ronzoni, Monica; Gianni, Luca; Rulli, Eliana; Poli, Davide; Galli, Francesca; Torri, Valter; De Simone, Irene; Galli, Fabio; Pasini, Felice; Rangoni, Giovanni; Venezia, Raffaele; Sozzi, Pietro; Nuzzo, Antonio; Berardi, Rossana; Frontini, Luciano; Rota, Silvia; Cozzi, Lorena; Cascinu, Stefano; Rosati, Gerardo; Bilancia, Domenico; Nasti, Guglielmo; Iaffaioli, Rosario Vincenzo; Lonardi, Sara; Zagonel, Vittorina; Zaniboni, Alberto; Marchetti, Paolo; Leone, Francesco; Giordano, Monica; Corsi, Domenico C.; Ferraãº, Francesco; Labianca, Roberto; Ronzoni, Monica; Scartozzi, Mario; Galli, Francesca
14	Treatment of metastatic melanoma: a multidisciplinary approach	2017	Fava, Paolo; Astrua, Chiara; Sanlorenzo, Martina; Ribero, Simone; Brizio, Matteo; Filippi, Andrea R; Marra, Elena; Picciotto, Franco; Sangiolo, Dario; Carnevale-Schianca, Fabrizio; Aglietta, Massimo; Sandrucci, Sergio; Ricardi, Umberto; Caliendo, Virginia; Quaglino, Pietro; Fierro, Maria T
15	Treating breast cancer with cell-based approaches: an overview	2017	Gallo, Susanna; Sangiolo, Dario; Carnevale Schianca, Fabrizio; Aglietta, Massimo; Montemurro, Filippo
16	Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer	2007	VALABREGA G; MONTEMURRO F; AGLIETTA M
17	Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial	2008	MONTEMURRO F; REDANA S; VALABREGA G; MARTINELLO R; AGLIETTA M; PALMIERO R
18	Trastuzumab-based combination therapy for breast cancer	2004	MONTEMURRO F; VALABREGA G; AGLIETTA M
19	Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison	2010	Redana S; Donadio M; Nolè F; Jacomuzzi ME; Beano A; Martinello R; Sapino A; Viale G; Aglietta M; Montemurro F.
20	Trastuzumab treatment in breast cancer	2006	MONTEMURRO F; VALABREGA G; AGLIETTA M